We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Next Gen Digital Diagnostic Platform to Detect Multiple Pathogens within 5 Minutes at Gene Level

By HospiMedica International staff writers
Posted on 30 Jun 2023
Image: The Check4 digital diagnostic platform aims to disrupt the PCR market for many infections (Photo courtesy of IdentifySensors)
Image: The Check4 digital diagnostic platform aims to disrupt the PCR market for many infections (Photo courtesy of IdentifySensors)

An advanced digital diagnostic platform with the capability to detect multiple pathogens in five minutes at the molecular gene level and priced significantly lower than current molecular tests is all set to disrupt the PCR market.

Check4 by IdentifySensors Biologics (Cleveland, OH, USA) is a next-generation digital diagnostic platform that has been developed to detect the genetic material of a wide range of pathogens for over-the-counter and point-of-care use. The Check4 testing platform comprises two components: a reusable Bluetooth reader roughly the size of a mobile phone, and disposable test cartridges that connect to the reader. Each test sample can simultaneously detect up to three different pathogens. Digital graphene sensors within the cartridges target conserved regions of the genome, thereby ensuring high sensitivity and specificity without the need for enzymatic amplification or reagents.

The sensors in the disposable cartridges can be customized to identify a broad range of pathogens that display similar symptoms. Multiplex tests are in development for respiratory pathogens (COVID, RSV, and influenza), gastrointestinal pathogens (Norovirus, Rotavirus, and Adenovirus), and sexually transmitted pathogens (HIV, Hepatitis, Chlamydia, Gonorrhea, and Herpes). Other tests under development include those for SEPSIS, MRSA, Lyme disease, and tropical pathogens such as Zika, Dengue, Yellow Fever, and West Nile virus. Previous research indicates that Check4 can potentially diagnose infections like COVID, RSV, and influenza even before patients exhibit symptoms. IdentifySensors has commenced testing this novel diagnostic device in anticipation of FDA submissions. Clinical studies for the Check4 diagnostic device are slated for this year as part of an extensive testing platform designed to be adapted for detecting a broad range of additional pathogens in the coming years.

"In preliminary studies we have seen encouraging results of this new technology," said Greg Hummer M.D., IdentifySensors co-founder and CEO. "We are excited to test these devices and move forward with additional targets that detect a wide range of infections."

Related Links:
IdentifySensors Biologics

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
MR Trolley
MR9002
New
Ultrasonic Dissector
SONICBEAT

Channels

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more